HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and maintained a $9 price target.
August 15, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and maintained a $9 price target.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation for Allogene Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100